Literature DB >> 9741499

A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial.

P A McCullough1, W W O'Neill, M Graham, R J Stomel, F Rogers, S David, A Farhat, R Kazlauskaite, M Al-Zagoum, C L Grines.   

Abstract

OBJECTIVES: The purpose of this study was to determine if early triage angiography with revascularization, if indicated, favorably affects clinical outcomes in patients with suspected acute myocardial infarction who are ineligible for thrombolysis.
BACKGROUND: The majority of patients with acute myocardial infarction and other acute coronary syndromes are considered ineligible for thrombolysis and therefore are not afforded the opportunity for early reperfusion.
METHODS: This multicenter, prospective, randomized trial evaluated in a controlled fashion the outcomes following triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Eligible patients (n=201) with <24 h of symptoms were randomized to early triage angiography and subsequent therapies based on the angiogram versus conventional medical therapy consisting of aspirin, intravenous heparin, nitroglycerin, beta-blockers, and analgesics.
RESULTS: In the triage angiography group, 109 patients underwent early angiography and 64 (58%) received revascularization, whereas in the conservative group, 54 (60%) subsequently underwent nonprotocol angiography in response to recurrent ischemia and 33 (37%) received revascularization (p=0.004). The mean time to revascularization was 27+/-32 versus 88+/-98 h (p=0.0001) and the primary endpoint of recurrent ischemic events or death occurred in 14 (13%) versus 31 (34%) of the triage angiography and conservative groups, respectively (45% risk reduction, 95% CI 27-59%, p=0.0002). There were no differences between the groups with respect to initial hospital costs or length of stay. Long-term follow-up at a median of 21 months revealed no significant differences in the endpoints of late revascularization, recurrent myocardial infarction, or all-cause mortality.
CONCLUSIONS: Early triage angiography in patients with acute coronary syndromes who are not eligible for thrombolytics reduced the composite of recurrent ischemic events or death and shortened the time to definitive revascularization during the index hospitalization. Despite more frequent early revascularization after triage angiography, we found no long-term benefit in cardiac outcomes compared with conservative medical therapy with revascularization prompted by recurrent ischemia.

Entities:  

Mesh:

Year:  1998        PMID: 9741499     DOI: 10.1016/s0735-1097(98)00284-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

Review 1.  Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit.

Authors: 
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

Review 2.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 3.  Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.

Authors:  David H Fitchett; Bjug Borgundvaag; Warren Cantor; Eric Cohen; Sanjay Dhingra; Stephen Fremes; Milan Gupta; Michael Heffernan; Heather Kertland; Mansoor Husain; Anatoly Langer; Eric Letovsky; Shaun G Goodman
Journal:  Can J Cardiol       Date:  2006-06       Impact factor: 5.223

4.  Risk stratification after acute myocardial infarction: is it time to reassess? Implications from the INSPIRE trial.

Authors:  John J Mahmarian; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

5.  Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI.

Authors:  Benjamin M Scirica; David A Morrow
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-02

6.  Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: A randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction.

Authors:  John J Mahmarian; Leslee J Shaw; Gerald H Olszewski; Bradley K Pounds; Maria E Frias; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

Review 7.  Early angiography in patients with chronic kidney disease: a collaborative systematic review.

Authors:  David M Charytan; Lars Wallentin; Bo Lagerqvist; Rudolf Spacek; Robbert J De Winter; Noam M Stern; Eugene Braunwald; Christopher P Cannon; Niteesh K Choudhry
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

8.  Associations between ST depression, four year mortality, and in-hospital revascularisation in unselected patients with non-ST elevation acute coronary syndromes.

Authors:  T A Hyde; J K French; C-K Wong; C Edwards; R M L Whitlock; H D White
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

9.  Among Unstable Angina and Non-ST-Elevation Myocardial Infarction Patients, Transient Myocardial Ischemia and Early Invasive Treatment Are Predictors of Major In-hospital Complications.

Authors:  Michele M Pelter; Denise L Loranger; Teri M Kozik; Anita Kedia; Richard P Ganchan; Deborah Ganchan; Xiao Hu; Mary G Carey
Journal:  J Cardiovasc Nurs       Date:  2016 Jul-Aug       Impact factor: 2.083

Review 10.  Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Authors:  Son V Pham; Phuong-Chi T Pham; Phuong-Mai T Pham; Jeffrey M Miller; Phuong-Thu T Pham; Phuong-Anh T Pham
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.